MASVE Interdepartmental Hepatology Center, Department of Experimental and clinical Medicine, University of Florence, Center for Research and Innovation CRIA-MASVE, AOU Careggi, Florence, Italy.
Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
J Clin Immunol. 2023 May;43(4):680-691. doi: 10.1007/s10875-023-01444-4. Epub 2023 Feb 16.
Mixed cryoglobulinemia syndrome (MCs) is a rare immunoproliferative systemic disorder with cutaneous and multiple organ involvement. Our multicenter survey study aimed to investigate the prevalence and outcome of COVID-19 and the safety and immunogenicity of COVID-19 vaccines in a large MCs series.
The survey included 430 unselected MCs patients (130 M, 300 F; mean age 70 ± 10.96 years) consecutively collected at 11 Italian referral centers. Disease classification, clinico-serological assessment, COVID-19 tests, and vaccination immunogenicity were carried out according to current methodologies.
A significantly higher prevalence of COVID-19 was found in MCs patients compared to Italian general population (11.9% vs 8.0%, p < 0.005), and the use of immunomodulators was associated to a higher risk to get infected (p = 0.0166). Moreover, higher mortality rate was recorded in MCs with COVID-19 compared to those without (p < 0.01). Patients' older age (≥ 60 years) correlated with worse COVID-19 outcomes. The 87% of patients underwent vaccination and 50% a booster dose. Of note, vaccine-related disease flares/worsening were significantly less frequent than those associated to COVID-19 (p = 0.0012). Impaired vaccination immunogenicity was observed in MCs patients compared to controls either after the first vaccination (p = 0.0039) and also after the booster dose (p = 0.05). Finally, some immunomodulators, namely, rituximab and glucocorticoids, hampered the vaccine-induced immunogenicity (p = 0.029).
The present survey revealed an increased prevalence and morbidity of COVID-19 in MCs patients, as well an impaired immunogenicity even after booster vaccination with high rate of no response. Therefore, MCs can be included among frail populations at high risk of infection and severe COVID-19 manifestations, suggesting the need of a close monitoring and specific preventive/therapeutical measures during the ongoing pandemic.
混合性冷球蛋白血症综合征(MCs)是一种罕见的免疫增殖性系统性疾病,伴有皮肤和多个器官受累。我们的多中心调查研究旨在调查 COVID-19 在大量 MCs 系列中的患病率和结局,以及 COVID-19 疫苗的安全性和免疫原性。
该调查包括在 11 个意大利转诊中心连续收集的 430 名未选择的 MCs 患者(130 名男性,300 名女性;平均年龄 70±10.96 岁)。根据当前方法进行疾病分类、临床血清学评估、COVID-19 检测和疫苗免疫原性。
与意大利普通人群相比,MCs 患者 COVID-19 的患病率明显更高(11.9%对 8.0%,p<0.005),免疫调节剂的使用与感染风险增加相关(p=0.0166)。此外,患有 COVID-19 的 MCs 患者的死亡率高于未患有 COVID-19 的患者(p<0.01)。患者年龄较大(≥60 岁)与 COVID-19 结局较差相关。87%的患者接受了疫苗接种,50%的患者接受了加强剂量。值得注意的是,与 COVID-19 相关的疫苗相关疾病发作/恶化的频率明显低于与 COVID-19 相关的频率(p=0.0012)。与对照组相比,MCs 患者在首次接种后(p=0.0039)和加强剂量后(p=0.05)的疫苗免疫原性受损。最后,一些免疫调节剂,即利妥昔单抗和糖皮质激素,阻碍了疫苗诱导的免疫原性(p=0.029)。
本调查显示 MCs 患者 COVID-19 的患病率和发病率增加,即使在加强接种后免疫原性也受损,且无反应率较高。因此,MCs 可以被包括在感染和严重 COVID-19 表现风险较高的脆弱人群中,这表明在当前大流行期间需要密切监测和采取特定的预防/治疗措施。